Based on these findings, the double-blind phase III MAESTRO-NASH trial enrolled over 950 non-cirrhotic patients, stratified by fibrosis stage (F1F3) and metabolic comorbidities [17]
Driven by excessive lymphatic flow due to portal hypertension and possible rupture of serosal lymphatics
Mechanisms of intestinal barrier dysfunction in sepsis
Multiple other causes must be considered , including haemorrhoids, inflammatory bowel disease, diverticular disease, polyps, or more serious conditions such as colorectal cancer
Safety Guide Wegovy (semaglutide 2.4 mg) is an MHRA-licensed GLP-1 receptor agonist for chronic weight management in adults meeting specific BMI criteria
It is vegan, non-GMO, and free from dairy, soy, and gluten, making it suitable for a range of dietary needs